Exosome Diagnostics, Inc., a Cambridge, MA-based developer of a liquid biopsy platform that enables non-invasive diagnosis of serious diseases, closed its $60m Series B financing.
Backers included Forbion Capital Partners, NGN Capital, and CD Ventures, as well as new investors, Qiagen, Arcus Ventures, Tiger Management and Blue Ridge Capital.
The company will use the funds to grow its commercial diagnostics, regulatory, and companion diagnostics divisions, as well as develop potential new diagnostic tests outside of oncology, such as in neurodegenerative diseases, and expand the development of its protein biomarker programs.
John Boyce, President and Chief Executive Officer, Exosome Diagnostics focuses on developing and commercializing biofluid-based diagnostics to deliver personalized precision healthcare. The company’s proprietary technology platform can achieve real-time access to comprehensive molecular information about cells in the body without direct access to the actual cells via liquid biopsy tests. by simultaneously isolating and analyzing exoRNA and cell-free DNA (cfDNA) to enhance detection of rare mutations.
Because it is exosome-based (exosomes are messengers released by all living cells into biofluids, such as plasma/serum, urine, cerebrospinal fluid and saliva and contain RNA, DNA and proteins from their cell of origin), the platform can be used to develop molecular tests not only for cancer, but potentially also for a number of non-cancer indications, including inflammatory, metabolic, cardiovascular, neurodegenerative, among other diseases.